NewsBenzinga엔라이벡스, 알로세트라 2b상 무릎 골관절염 임상시험에서 계획된 182명 중 135명 무작위 배정 및 투여 완료 발표···2027년 중반까지 6개월 주요 데이터 발표 예정 엔라이벡스, 알로세트라 2b상 무릎 골관절염 임상시험에서 계획된 182명 중 135명 무작위 배정 및 투여 완료 발표···2027년 중반까지 6개월 주요 데이터 발표 예정 Benzinga 2026.10.28 12:01 (GMT+0) Open on Benzinga Other news Ark Invest Makes Big Crypto-Related Buys Yesterday While Selling $84.8M in Nvidia Stock Abraxas Capital Closes Most of Its Hyperliquid Shorts, Account Value Down to Just $22.4 Million Nvidia Falls 35% From Record High, Short Sellers Sit on $24 Billion in Paper Profits Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory Evernorth Has Written Down Its Pre-Listing XRP Holdings by 60%
Nvidia Director Reportedly Warns of ‘Irreplaceable Talent’ Loss: Board Urged to Bring Back Jensen Huang as NVDA Stock Slips
Elon Musk’s Cybercab Ambitions Get a $3.3 Billion Boost — Tesla Plans 1 Million Units a Year at Berlin Factory